In 42 hospitalized schizophrenia patients, 800 mg/day CBD produced symptom improvement identical to amisulpride (PANSS improvement 30.5 vs 30.1) while causing significantly less weight gain, fewer movement disorders, and no prolactin elevation.
Read this if you want to understand the strongest evidence that CBD has genuine antipsychotic properties and how it works through a fundamentally different mechanism than existing medications.
CBD matched amisulpride for schizophrenia symptom reduction (PANSS 30.5 vs 30.1) with dramatically fewer side effects
The Backstory
Here's a sentence that sounds impossible: a compound from the same plant associated with psychosis can treat psychosis — and match the performance of a standard antipsychotic medication while producing almost none of its devastating side effects.
In 2012, Markus Leweke proved it.
The Trial
Leweke, a German psychiatrist who had been studying the endocannabinoid system's role in schizophrenia since the mid-1990s, designed the trial that the field had been waiting for. Forty-two patients hospitalized for acute schizophrenic episodes were randomized to receive either 800 mg/day of CBD or 800 mg/day of amisulpride — a potent second-generation antipsychotic widely prescribed in Europe — for four weeks.
The choice of amisulpride as the comparator was deliberate and gutsy. This wasn't CBD versus placebo. It was CBD versus a drug that works. The question wasn't whether CBD could do something — it was whether CBD could match the best that conventional psychiatry had to offer.
Both groups started at 200 mg/day and escalated to 800 mg over the first week. Lorazepam was allowed for acute agitation. Patients were assessed with the PANSS (Positive and Negative Syndrome Scale) — the gold-standard measure of psychotic symptoms — at baseline, day 14, and day 28.
CBD vs Amisulpride
Four Weeks of Treatment for Acute Schizophrenia
30.5
CBD PANSS improvement
points at day 28 (p<0.001 vs baseline)
30.1
Amisulpride PANSS improvement
points at day 28 (p<0.001 vs baseline)
p=0.884
Between-group difference
no statistically significant difference — treatments were equivalent
75% vs 74%
Response rates
nearly identical clinical response (≥20% PANSS improvement)
Leweke et al. (2012), Transl Psychiatry 2:e94
Both treatments worked. Both produced statistically significant improvements in total psychotic symptoms, positive symptoms (hallucinations, delusions), negative symptoms (flat affect, social withdrawal), and general psychopathology. Response rates were virtually identical: 75% for CBD, 74% for amisulpride. The between-group difference on the primary outcome was 1.0 PANSS points — clinically meaningless.
But the side effect profiles were not equivalent. They weren't even close.
The Side Effect Revolution
Supporting arguments
- Significantly fewer extrapyramidal symptoms (movement disorders) with CBD vs amisulpride (p=0.006)
- Significantly less weight gain with CBD (p=0.010) — antipsychotic weight gain is a major driver of metabolic syndrome and cardiovascular death
- Significantly lower prolactin elevation with CBD (p<0.001) — elevated prolactin causes sexual dysfunction, breast enlargement, and galactorrhea
- No significant effects on hepatic or cardiac function from CBD
- CBD did not cause sedation, cognitive impairment, or the characteristic 'zombie' effect of antipsychotics
Limitations and counterarguments
- Only 42 patients — far too small for definitive efficacy or rare adverse event detection
- Non-inferiority could not be formally demonstrated statistically (CI too wide with small sample)
- CBD monotherapy — no data on whether this works long-term or in treatment-resistant cases
- Study terminated early due to funding expiration and difficulty recruiting (cannabinoid-positive patients excluded)
- Lorazepam co-medication was unevenly distributed (amisulpride group used significantly more at baseline)
Leweke et al. (2012)
The antipsychotic medications that constitute the standard of care for schizophrenia work, but at a terrible cost. Weight gains of 10-20 kg are common. Movement disorders — tremors, rigidity, involuntary facial movements — afflict a significant minority. Sexual dysfunction from prolactin elevation drives medication non-adherence, which drives relapse, which drives hospitalization. Many patients describe feeling like a different (worse) person on antipsychotics.
CBD produced none of this. Equal symptom reduction. No movement disorders. No weight gain. No sexual dysfunction. For a disease that requires lifelong medication and where side effects are the primary reason patients stop taking their drugs, a treatment with this side effect profile would be transformative.
The Mechanism: Not Dopamine — Anandamide
Perhaps the most important finding wasn't clinical. It was mechanistic.
Biological Mechanism
How CBD Fights Psychosis (Without Blocking Dopamine)
Standard antipsychotics block dopamine
Amisulpride and most antipsychotics work by blocking D2 dopamine receptors. This reduces psychosis but also causes movement disorders, weight gain, and prolactin elevation — all dopamine-related side effects.
CBD does not block dopamine
At therapeutic concentrations, CBD does not significantly interact with dopamine, glutamate, or serotonin receptors — the conventional antipsychotic targets.
CBD inhibits FAAH
CBD blocks fatty acid amide hydrolase (FAAH), the enzyme that breaks down anandamide — the brain's own endocannabinoid. This causes anandamide levels to rise.
Anandamide levels increase
Serum anandamide levels increased significantly in CBD-treated patients compared to amisulpride-treated patients (p<0.001 at day 28).
Higher anandamide = better outcomes
In CBD-treated patients, higher anandamide levels were significantly correlated with greater clinical improvement (p=0.0012). This correlation was absent in the amisulpride group.
A new mechanism for psychosis treatment
CBD treats psychosis by enhancing the brain's endogenous cannabinoid signaling — a completely novel therapeutic approach that explains the favorable side effect profile.
Leweke et al. (2012)
This is the finding that makes this study more than just a clinical comparison. Leweke didn't just show that CBD works — he showed how it works, and the mechanism is fundamentally different from any existing antipsychotic. Every current antipsychotic medication, from first-generation (chlorpromazine, haloperidol) to second-generation (risperidone, olanzapine, amisulpride), works primarily by blocking dopamine signaling. CBD doesn't touch dopamine. It enhances the brain's own endocannabinoid system.
The correlation between anandamide increase and clinical improvement (p=0.0012) is especially compelling because it's mechanism-specific. The correlation existed only in CBD-treated patients, not in amisulpride-treated patients. This isn't a nonspecific effect of getting better — it's a direct link between CBD's known pharmacology and clinical outcome.
The Irony
The deepest irony of this study is the irony of cannabis itself. THC — the psychoactive component that produces the high — is associated with increased psychosis risk, particularly in high-potency products used in adolescence. CBD — the non-psychoactive component that moderates THC's effects — appears to treat psychosis.
The same plant contains both a potential cause and a potential cure for the same disease. This isn't a contradiction — it reflects the fundamental pharmacological duality of cannabis. THC overstimulates CB1 receptors, producing the acute psychotomimetic effects well-documented in Bhattacharyya's neuroimaging work. CBD enhances anandamide signaling, which appears to normalize the same circuits.
Leweke himself had proposed the "cannabinoid hypothesis of schizophrenia" in 1997 — the idea that the endocannabinoid system is dysregulated in psychosis. This study was the clinical vindication of that hypothesis, fifteen years later.
Where It Went Next
Leweke's trial was monotherapy — CBD alone versus antipsychotic alone. The larger follow-up, led by Philip McGuire at King's College London, tested CBD as an adjunct — added on top of existing antipsychotic treatment.
McGuire's 2018 Phase II trial (published in the American Journal of Psychiatry) randomized 88 patients to 1,000 mg/day CBD or placebo alongside their usual antipsychotic. The CBD group showed significantly lower positive symptoms (PANSS positive subscale: treatment difference -1.4, 95% CI -2.5 to -0.2), greater clinician-rated improvement, and were more likely to be rated as not severely unwell. Negative symptoms and general psychopathology did not significantly differ.
The McGuire trial confirmed the signal but was more modest — CBD as an add-on produced statistically significant but smaller improvements than CBD as monotherapy. This is the typical pattern: add-on trials show smaller effects because the baseline medication is already doing most of the work.
Research Timeline
Historical research record
Why This Hasn't Changed Clinical Practice (Yet)
Despite the elegance of the finding, CBD has not become a standard schizophrenia treatment. The reasons are instructive:
The 2012 trial had only 42 patients. Phase III trials with hundreds of patients haven't been completed. Regulatory approval requires far more data than a single Phase II study provides. The 800 mg daily dose is expensive and impractical with consumer-grade CBD products. And the psychiatric establishment moves slowly, particularly for compounds derived from cannabis — a drug associated with psychosis in public perception.
There's also a scientific gap. CBD monotherapy replacing antipsychotics is a much more radical proposition than CBD as an adjunct. The McGuire trial tested the safer proposition (add-on) and found a real but modest effect. Whether the dramatic Leweke result — full equivalence — would replicate in a larger monotherapy trial is genuinely unknown.
Key Takeaways
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012) · Translational Psychiatry
Can CBD replace antipsychotic medications for schizophrenia?
This single trial of 42 patients showed CBD matched amisulpride for symptom reduction. But one small trial is not enough to change clinical practice. No Phase III replication exists. If you have schizophrenia, do not stop your antipsychotic medication to try CBD. Uncontrolled psychosis is dangerous. Discuss CBD as a potential adjunct with your psychiatrist, but do not treat this study as a clinical recommendation.
How does CBD treat psychosis if cannabis causes psychosis?
Cannabis contains both THC (which overstimulates CB1 receptors and can trigger psychotic episodes) and CBD (which enhances anandamide signaling and appears to reduce psychotic symptoms). These are opposing effects from different compounds. THC's psychosis risk is dose-dependent and strongest in high-potency products lacking CBD. CBD's antipsychotic effect works through an entirely different mechanism — not dopamine blockade, but endocannabinoid enhancement.
Why isn't CBD already used as an antipsychotic?
Several barriers: only one small monotherapy trial exists, the dose required (800 mg/day) is expensive, regulatory approval requires Phase III trials that haven't been conducted, and the psychiatric establishment is understandably cautious about cannabis-derived treatments for a disorder associated with cannabis use. The mechanism is promising, but the evidence base isn't yet sufficient for clinical adoption.
What is FAAH and why does it matter?
FAAH (fatty acid amide hydrolase) is the enzyme that breaks down anandamide, the brain's own cannabinoid. CBD inhibits FAAH, causing anandamide levels to rise. In this trial, higher anandamide levels correlated with better symptom improvement. This suggests that psychosis may partly result from insufficient endocannabinoid signaling, and that enhancing this signaling — rather than blocking dopamine — could be a viable treatment approach.
What the researchers found
PANSS total improvement: CBD 30.5 (±16.4) vs amisulpride 30.1 (±24.7), p=0.884. Response rates (≥20% improvement): 75% CBD vs 74% amisulpride. CBD significantly better on: extrapyramidal symptoms (p=0.006), weight gain (p=0.010), prolactin elevation (p<0.001). Anandamide levels increased significantly with CBD vs amisulpride (p<0.001 at day 28). Anandamide increase correlated with symptom improvement in CBD group (p=0.0012) but not amisulpride group (p=0.64).
Why it matters
This is the first randomized trial showing CBD can match a conventional antipsychotic for efficacy while producing dramatically fewer side effects — and through a completely novel mechanism (FAAH inhibition / anandamide enhancement rather than dopamine blockade). Antipsychotic side effects drive medication non-adherence, which drives relapse. A treatment with equivalent efficacy and minimal side effects would transform schizophrenia management.
How the study worked
Double-blind, randomized, parallel-group, Phase II active-controlled trial (CBD-CT1; NCT00628290). 42 acutely exacerbated schizophrenic inpatients randomized 1:1 to CBD 800 mg/day or amisulpride 800 mg/day for 28 days. Both escalated from 200 mg/day over first week. Lorazepam permitted for agitation. Assessed with PANSS (primary), BPRS, CGI, EPS scale, metabolic markers. MMRM statistical analysis. Approved by University of Cologne Ethics Committee. Funded by Stanley Medical Research Institute and NIDA.
What this study cannot tell us
Only 42 patients — too small for definitive conclusions or rare adverse event detection. Non-inferiority could not be formally demonstrated (confidence intervals too wide). Study terminated early due to funding expiration. Cannabinoid-positive patients excluded, limiting recruitment. Baseline lorazepam use was significantly higher in the amisulpride group (p=0.006). CBD monotherapy — no data on long-term use or treatment-resistant cases.
How to read the evidence
Double-blind, randomized, active-controlled Phase II trial — strong design. But only 42 patients, terminated early, non-inferiority not formally demonstrated. Highly promising but not definitive.
When this study was published
Published in 2012. McGuire 2018 confirmed CBD's antipsychotic properties as an adjunct. No Phase III monotherapy trial has been completed. Leweke co-founded Endosane Pharmaceuticals in 2020 to develop FAAH-based treatments.
The bigger picture
Every antipsychotic since chlorpromazine (1952) has worked by blocking dopamine. Leweke showed CBD works through an entirely different mechanism — enhancing the endocannabinoid system. If validated in larger trials, this would represent the first genuinely new approach to treating psychosis in seven decades. McGuire's 2018 Phase II add-on trial (88 patients, Am J Psychiatry) confirmed the signal but with smaller effect sizes.
Questions still open
- Would CBD monotherapy replicate this equivalence in a larger Phase III trial? Is CBD effective for treatment-resistant schizophrenia? What is the optimal CBD dose — would lower doses work? Could FAAH inhibitors (pharmacological descendants of this finding) be more potent? Is CBD safe and effective for long-term maintenance therapy?
Common questions
Can CBD treat schizophrenia?
How does CBD work for psychosis?
Why didn't CBD cause the same side effects as amisulpride?
Read the original research
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Translational Psychiatry, 2, e94
Citation
Leweke, F Markus; Piomelli, Daniele; Pahlisch, Franziska; Muhl, Dagmar; Gerth, Christoph W; Hoyer, Carolin; Klosterkötter, Joachim; Hellmich, Martin; Koethe, Dagmar. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.. Translational Psychiatry, 2, e94. https://doi.org/10.1038/tp.2012.15